These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

740 related items for PubMed ID: 24194352

  • 1. FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.
    Chung HW, Lee KY, Kim HJ, Kim WS, So Y.
    J Cancer Res Clin Oncol; 2014 Jan; 140(1):89-98. PubMed ID: 24194352
    [Abstract] [Full Text] [Related]

  • 2. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H, Wroblewski K, Liao S, Kampalath R, Penney BC, Zhang Y, Pu Y.
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [Abstract] [Full Text] [Related]

  • 3. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH, Chiu NT, Su WC, Guo HR, Lee BF.
    Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
    [Abstract] [Full Text] [Related]

  • 4. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S, Penney BC, Wroblewski K, Zhang H, Simon CA, Kampalath R, Shih MC, Shimada N, Chen S, Salgia R, Appelbaum DE, Suzuki K, Chen CT, Pu Y.
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [Abstract] [Full Text] [Related]

  • 5. Differential expression and prognostic significance of GLUT1 according to histologic type of non-small-cell lung cancer and its association with volume-dependent parameters.
    Koh YW, Lee SJ, Park SY.
    Lung Cancer; 2017 Feb; 104():31-37. PubMed ID: 28212997
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Volumetric PET parameters can predict overall survival in advanced lung adenocarcinoma.
    Yanarateş A, Yazici B.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020 Feb; 39(1):3-8. PubMed ID: 31818695
    [Abstract] [Full Text] [Related]

  • 8. [Evaluate the value of (18)F-FDG PET-CT imaging in predicting the mutationsin epidermal growth factor receptor in lung adenocarcinoma].
    Ding CY, Yang WP, Guo Z, Sun J, Li YY, Li TR.
    Zhonghua Zhong Liu Za Zhi; 2017 Jul 23; 39(7):528-531. PubMed ID: 28728300
    [Abstract] [Full Text] [Related]

  • 9. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Hwang SH, Cho A, Yun M, Choi YD, Rha SY, Kang WJ.
    Clin Nucl Med; 2017 May 23; 42(5):e235-e241. PubMed ID: 28288043
    [Abstract] [Full Text] [Related]

  • 10. [Semiquantitative parameters of 18F-FDG PET/CT, gene mutation states of epidermal growth factor receptor and anaplastic lymphoma kinase in prognosis evaluation of patients with lung adenocarcinoma].
    Liao XH, Wang RF, Liu M, Chen XQ, Xiong Y, Nong L, Yin L, Zhang BY, DU YJ.
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Oct 20; 53(2):246-254. PubMed ID: 33879893
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
    Wu LL, Liang JH, Wang L, Xu W, Ding CY.
    Zhonghua Zhong Liu Za Zhi; 2019 Nov 23; 41(11):831-836. PubMed ID: 31770850
    [Abstract] [Full Text] [Related]

  • 13. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
    Ryu IS, Kim JS, Roh JL, Lee JH, Cho KJ, Choi SH, Nam SY, Kim SY.
    J Nucl Med; 2013 Jul 23; 54(7):1032-8. PubMed ID: 23670902
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Combination of circulating tumor cells and 18F-FDG PET/CT for precision diagnosis in patients with non-small cell lung cancer.
    Sun M, Lu D, Li X, Wang J, Zhang L, Yang P, Yang Y, Shen J.
    Cancer Med; 2024 Sep 23; 13(18):e70216. PubMed ID: 39302034
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Application of novel quantitative techniques for fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer.
    Wang D, Koh ES, Descallar J, Pramana A, Vinod SK, Ho Shon I.
    Asia Pac J Clin Oncol; 2016 Dec 23; 12(4):349-358. PubMed ID: 27550522
    [Abstract] [Full Text] [Related]

  • 20. Artificial intelligence-based, volumetric assessment of the bone marrow metabolic activity in [18F]FDG PET/CT predicts survival in multiple myeloma.
    Sachpekidis C, Enqvist O, Ulén J, Kopp-Schneider A, Pan L, Mai EK, Hajiyianni M, Merz M, Raab MS, Jauch A, Goldschmidt H, Edenbrandt L, Dimitrakopoulou-Strauss A.
    Eur J Nucl Med Mol Imaging; 2024 Jul 23; 51(8):2293-2307. PubMed ID: 38456971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.